EP1619254A1 - Transfer von mRNA unter Verwendung von polykationischen Verbindungen - Google Patents

Transfer von mRNA unter Verwendung von polykationischen Verbindungen Download PDF

Info

Publication number
EP1619254A1
EP1619254A1 EP05022610A EP05022610A EP1619254A1 EP 1619254 A1 EP1619254 A1 EP 1619254A1 EP 05022610 A EP05022610 A EP 05022610A EP 05022610 A EP05022610 A EP 05022610A EP 1619254 A1 EP1619254 A1 EP 1619254A1
Authority
EP
European Patent Office
Prior art keywords
mrna
rna
complex
protamine
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP05022610A
Other languages
English (en)
French (fr)
Other versions
EP1619254B1 (de
Inventor
Ingmar Hoerr
Hans-Georg Prof. Dr. Rammensee
Günther Prof. Dr. Jung
Reinhard Dr. Obst
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Curevac SE
Original Assignee
Curevac AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curevac AG filed Critical Curevac AG
Priority to EP05022610A priority Critical patent/EP1619254B1/de
Priority to DE69943068T priority patent/DE69943068D1/de
Priority to AT05022610T priority patent/ATE492644T1/de
Publication of EP1619254A1 publication Critical patent/EP1619254A1/de
Application granted granted Critical
Publication of EP1619254B1 publication Critical patent/EP1619254B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
EP05022610A 1999-09-09 1999-09-09 Transfer von mRNA unter Verwendung von polykationischen Verbindungen Expired - Lifetime EP1619254B1 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP05022610A EP1619254B1 (de) 1999-09-09 1999-09-09 Transfer von mRNA unter Verwendung von polykationischen Verbindungen
DE69943068T DE69943068D1 (de) 1999-09-09 1999-09-09 Transfer von mRNA unter Verwendung von polykationischen Verbindungen
AT05022610T ATE492644T1 (de) 1999-09-09 1999-09-09 Transfer von mrna unter verwendung von polykationischen verbindungen

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05002916A EP1541690A3 (de) 1999-09-09 1999-09-09 Transfer von mRNA unter Verwendung von polykationischen Verbindungen
EP99117771A EP1083232B1 (de) 1999-09-09 1999-09-09 Transfer von mRNAs unter Verwendung von polykationischen Verbindungen
EP05022610A EP1619254B1 (de) 1999-09-09 1999-09-09 Transfer von mRNA unter Verwendung von polykationischen Verbindungen

Related Parent Applications (3)

Application Number Title Priority Date Filing Date
EP05002916A Division EP1541690A3 (de) 1999-09-09 1999-09-09 Transfer von mRNA unter Verwendung von polykationischen Verbindungen
EP99117771.8 Division 1999-09-09
EP05002916.4 Division 2005-02-11

Publications (2)

Publication Number Publication Date
EP1619254A1 true EP1619254A1 (de) 2006-01-25
EP1619254B1 EP1619254B1 (de) 2010-12-22

Family

ID=8238953

Family Applications (4)

Application Number Title Priority Date Filing Date
EP05002916A Withdrawn EP1541690A3 (de) 1999-09-09 1999-09-09 Transfer von mRNA unter Verwendung von polykationischen Verbindungen
EP07002200A Withdrawn EP1818409A1 (de) 1999-09-09 1999-09-09 Transfer von mRNA unter Verwendung von polykationischen Verbindungen
EP05022610A Expired - Lifetime EP1619254B1 (de) 1999-09-09 1999-09-09 Transfer von mRNA unter Verwendung von polykationischen Verbindungen
EP99117771A Expired - Lifetime EP1083232B1 (de) 1999-09-09 1999-09-09 Transfer von mRNAs unter Verwendung von polykationischen Verbindungen

Family Applications Before (2)

Application Number Title Priority Date Filing Date
EP05002916A Withdrawn EP1541690A3 (de) 1999-09-09 1999-09-09 Transfer von mRNA unter Verwendung von polykationischen Verbindungen
EP07002200A Withdrawn EP1818409A1 (de) 1999-09-09 1999-09-09 Transfer von mRNA unter Verwendung von polykationischen Verbindungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP99117771A Expired - Lifetime EP1083232B1 (de) 1999-09-09 1999-09-09 Transfer von mRNAs unter Verwendung von polykationischen Verbindungen

Country Status (4)

Country Link
EP (4) EP1541690A3 (de)
AT (2) ATE289630T1 (de)
DE (2) DE69943068D1 (de)
ES (1) ES2238799T3 (de)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP2101823B1 (de) 2007-01-09 2016-11-23 CureVac AG Rna-kodierter antikörper
US9657295B2 (en) 2010-10-01 2017-05-23 Modernatx, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9814760B2 (en) 2012-04-02 2017-11-14 Modernatx, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9828416B2 (en) 2012-04-02 2017-11-28 Modernatx, Inc. Modified polynucleotides for the production of secreted proteins
US9827332B2 (en) 2012-04-02 2017-11-28 Modernatx, Inc. Modified polynucleotides for the production of proteins
US9872900B2 (en) 2014-04-23 2018-01-23 Modernatx, Inc. Nucleic acid vaccines
US9937233B2 (en) 2010-08-06 2018-04-10 Modernatx, Inc. Engineered nucleic acids and methods of use thereof
US10077439B2 (en) 2013-03-15 2018-09-18 Modernatx, Inc. Removal of DNA fragments in mRNA production process
US10138507B2 (en) 2013-03-15 2018-11-27 Modernatx, Inc. Manufacturing methods for production of RNA transcripts
US10286086B2 (en) 2014-06-19 2019-05-14 Modernatx, Inc. Alternative nucleic acid molecules and uses thereof
US10385088B2 (en) 2013-10-02 2019-08-20 Modernatx, Inc. Polynucleotide molecules and uses thereof
US10407683B2 (en) 2014-07-16 2019-09-10 Modernatx, Inc. Circular polynucleotides
US10590161B2 (en) 2013-03-15 2020-03-17 Modernatx, Inc. Ion exchange purification of mRNA
US10751386B2 (en) 2011-09-12 2020-08-25 Modernatx, Inc. Engineered nucleic acids and methods of use thereof
US10815291B2 (en) 2013-09-30 2020-10-27 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
US10898574B2 (en) 2011-03-31 2021-01-26 Modernatx, Inc. Delivery and formulation of engineered nucleic acids
US11027025B2 (en) 2013-07-11 2021-06-08 Modernatx, Inc. Compositions comprising synthetic polynucleotides encoding CRISPR related proteins and synthetic sgRNAs and methods of use
US11377470B2 (en) 2013-03-15 2022-07-05 Modernatx, Inc. Ribonucleic acid purification
EP4035659A1 (de) 2016-11-29 2022-08-03 PureTech LYT, Inc. Exosome zur ausgabe von therapeutischen wirkstoffen
US11434486B2 (en) 2015-09-17 2022-09-06 Modernatx, Inc. Polynucleotides containing a morpholino linker

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001030847A1 (en) * 1999-10-22 2001-05-03 Aventis Pasteur Limited Modified gp100 and uses thereof
ATE376434T1 (de) * 2001-04-21 2007-11-15 Curevac Gmbh Injektionsgerät für mrna applikation
EP2305699B1 (de) 2001-06-05 2014-08-13 CureVac GmbH Stabilisierte mRNA mit erhöhtem G/C-Gehalt und optimierter Codon Usage für die Impfung gegen Schlafkrankheit, Leishmaniose und Toxoplasmose
DE10162480A1 (de) * 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
FR2845918A1 (fr) * 2002-10-16 2004-04-23 Pasteur Institut Preparations immunogenes et vaccinantes a base d'arn
WO2003059381A2 (en) * 2002-01-18 2003-07-24 Curevac Gmbh Immunogenic preparations and vaccines on the basis of mrna
DE10229872A1 (de) 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
SG176314A1 (en) 2002-12-31 2011-12-29 Altus Pharmaceuticals Inc Human growth hormone crystals and methods for preparing them
DE10335833A1 (de) 2003-08-05 2005-03-03 Curevac Gmbh Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
GB0501125D0 (en) * 2005-01-19 2005-02-23 Ribostem Ltd Method of genotypically modifying cells by administration of rna
WO2006046978A2 (en) * 2004-06-28 2006-05-04 Argos Therapeutics, Inc. Cationic peptide-mediated transformation
DE102004042546A1 (de) 2004-09-02 2006-03-09 Curevac Gmbh Kombinationstherapie zur Immunstimulation
EP2742951B1 (de) 2004-09-14 2016-02-03 Argos Therapeutics, Inc. Stammunabhängige Amplifikation von HIV Polynucleotiden
DE102005023170A1 (de) 2005-05-19 2006-11-23 Curevac Gmbh Optimierte Formulierung für mRNA
ES2698600T3 (es) 2005-12-13 2019-02-05 Univ Pennsylvania Métodos para transfectar ácidos nucleicos en células vivas
US9157066B2 (en) 2005-12-13 2015-10-13 The Trustees Of The University Of Pennsylvania Transcriptome transfer produces cellular phenotype conversion
US10647960B2 (en) 2005-12-13 2020-05-12 The Trustees Of The University Of Pennsylvania Transcriptome transfer produces cellular phenotype conversion
DE102006035618A1 (de) 2006-07-31 2008-02-07 Curevac Gmbh Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz
AU2007280690C1 (en) 2006-07-31 2012-08-23 Curevac Gmbh Nucleic acid of formula (I): GIXmGn, or (II): CIXmCn, in particular as an immune-stimulating agent/adjuvant
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
WO2009046739A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating prostate cancer (pca)
EP2195015B1 (de) 2007-10-09 2017-04-12 CureVac AG Zusammensetzung zur behandlung von prostatakrebs (pca)
WO2009046738A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
EP2548960B1 (de) 2008-01-31 2018-01-31 CureVac AG Nukleinsäure der Formel (NuGIXmGnNv)a und Derivate davon als immunstimulierendes Mittel/Adjuvans
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
WO2011069529A1 (en) 2009-12-09 2011-06-16 Curevac Gmbh Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
WO2011069528A1 (en) 2009-12-09 2011-06-16 Curevac Gmbh Lyophilization of nucleic acids in lactate-containing solutions
EP2387999A1 (de) 2010-05-21 2011-11-23 CureVac GmbH Histidin enthaltende Lösung zur Transfektion und/oder Injektion von Nukleinsäuren und deren Verwendungen
PL2590626T3 (pl) 2010-07-06 2016-04-29 Glaxosmithkline Biologicals Sa Liposomy z lipidami o korzystnej wartości pka do dostarczania rna
CA2804494A1 (en) 2010-07-06 2012-01-12 Novartis Ag Virion-like delivery particles for self-replicating rna molecules
WO2012006369A2 (en) 2010-07-06 2012-01-12 Novartis Ag Immunisation of large mammals with low doses of rna
ES2770335T3 (es) 2010-07-06 2020-07-01 Glaxosmithkline Biologicals Sa Administración de ARN para desencadenar múltiples vías inmunológicas
LT3981427T (lt) 2010-08-31 2022-08-10 Glaxosmithkline Biologicals S.A. Pegilintos liposomos, skirtos imunogeną koduojančios rnr pristatymui
MX363307B (es) 2010-10-11 2019-03-20 Novartis Ag Star Plataformas para suministro de antigenos.
WO2012103985A2 (en) * 2010-12-16 2012-08-09 Steve Pascolo Pharmaceutical composition consisting of rna having alkali metal as counter ion and formulated with dications
WO2012116715A1 (en) * 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
WO2012113413A1 (en) 2011-02-21 2012-08-30 Curevac Gmbh Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
EP3473265A1 (de) * 2011-03-02 2019-04-24 CureVac AG Impfung alter patienten
CA2840989A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic combination compositions and uses thereof
RU2628705C2 (ru) * 2011-08-31 2017-08-21 Новартис Аг Пегилированные липосомы для доставки кодирующей иммуноген рнк
EP3682905B1 (de) 2011-10-03 2021-12-01 ModernaTX, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
JP2013095755A (ja) * 2011-11-02 2013-05-20 Kyowa Hakko Kirin Co Ltd カチオン性脂質
EP2791160B1 (de) 2011-12-16 2022-03-02 ModernaTX, Inc. Modifizierte mrna zusammensetzungen
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
EP4074834A1 (de) 2012-11-26 2022-10-19 ModernaTX, Inc. Am kettenende modifizierte rna
WO2014186334A1 (en) 2013-05-15 2014-11-20 Robert Kruse Intracellular translation of circular rna
AU2014310934B2 (en) 2013-08-21 2019-09-12 CureVac SE Respiratory syncytial virus (RSV) vaccine
EP3035955B1 (de) 2013-08-21 2019-09-11 CureVac AG Zusammensetzung und impfstoff zur behandlung von lungenkrebs
CA2926218A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
CA2925021A1 (en) 2013-11-01 2015-05-07 Curevac Ag Modified rna with decreased immunostimulatory properties
WO2015149944A2 (en) 2014-04-01 2015-10-08 Curevac Gmbh Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
US9738593B2 (en) 2014-06-25 2017-08-22 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
SG11201707663SA (en) 2015-04-17 2017-11-29 Curevac Ag Lyophilization of rna
ES2746340T3 (es) 2015-04-22 2020-03-05 Curevac Ag Composición que contiene ARN para el tratamiento de enfermedades tumorales
WO2016180430A1 (en) 2015-05-08 2016-11-17 Curevac Ag Method for producing rna
EP3928800A3 (de) 2015-05-20 2022-03-23 CureVac AG Trockenpulverzusammensetzung mit langkettiger rna
IL283545B2 (en) 2015-06-29 2023-09-01 Acuitas Therapeutics Inc Lipids and nanoparticulate lipid formulations for delivery of nucleic acids
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
EP3324979B1 (de) 2015-07-21 2022-10-12 ModernaTX, Inc. Impfstoffe gegen infektionserkrankungen
EP4011451A1 (de) 2015-10-22 2022-06-15 ModernaTX, Inc. Impfstoffe gegen atemwegsvirus
CA3002819A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Sexually transmitted disease vaccines
EP3364981A4 (de) 2015-10-22 2019-08-07 ModernaTX, Inc. Impfstoff gegen das humane cytomegalovirus
EP3364950A4 (de) 2015-10-22 2019-10-23 ModernaTX, Inc. Impfstoffe gegen tropenkrankheiten
CA3002912A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Nucleic acid vaccines for varicella zoster virus (vzv)
PL3368507T3 (pl) 2015-10-28 2023-03-27 Acuitas Therapeutics Inc. Nowe preparaty lipidów i nanocząstek lipidowych do dostarczania kwasów nukleinowych
CN108778308A (zh) * 2015-12-22 2018-11-09 库瑞瓦格股份公司 生产rna分子组合物的方法
WO2017191264A1 (en) 2016-05-04 2017-11-09 Curevac Ag Nucleic acid molecules and uses thereof
CA3023174A1 (en) 2016-06-09 2017-12-14 Curevac Ag Hybrid carriers for nucleic acid cargo
WO2017212006A1 (en) * 2016-06-09 2017-12-14 Curevac Ag Hybrid carriers for nucleic acid cargo
WO2018033254A2 (en) 2016-08-19 2018-02-22 Curevac Ag Rna for cancer therapy
JP6980780B2 (ja) 2016-10-21 2021-12-15 モデルナティーエックス， インコーポレイテッド ヒトサイトメガロウイルスワクチン
AU2017350488B2 (en) 2016-10-26 2022-06-23 Acuitas Therapeutics Inc. Lipid nanoparticle mRNA vaccines
US10925958B2 (en) 2016-11-11 2021-02-23 Modernatx, Inc. Influenza vaccine
US11103578B2 (en) 2016-12-08 2021-08-31 Modernatx, Inc. Respiratory virus nucleic acid vaccines
WO2018151816A1 (en) 2017-02-16 2018-08-23 Modernatx, Inc. High potency immunogenic compositions
US11045540B2 (en) 2017-03-15 2021-06-29 Modernatx, Inc. Varicella zoster virus (VZV) vaccine
MA52262A (fr) 2017-03-15 2020-02-19 Modernatx Inc Vaccin à large spectre contre le virus de la grippe
MA47787A (fr) 2017-03-15 2020-01-22 Modernatx Inc Vaccin contre le virus respiratoire syncytial
US11752206B2 (en) 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
MA47790A (fr) 2017-03-17 2021-05-05 Modernatx Inc Vaccins à base d'arn contre des maladies zoonotiques
US11357856B2 (en) 2017-04-13 2022-06-14 Acuitas Therapeutics, Inc. Lipids for delivery of active agents
CA3061612A1 (en) 2017-04-28 2018-11-01 Acuitas Therapeutics, Inc. Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
JP7237825B2 (ja) * 2017-05-26 2023-03-13 公益財団法人川崎市産業振興財団 血中におけるｒｎａの安定性の改善剤および投与方法
CA3073020A1 (en) 2017-08-16 2019-02-21 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
US11542225B2 (en) 2017-08-17 2023-01-03 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
US11524932B2 (en) 2017-08-17 2022-12-13 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
US10653767B2 (en) 2017-09-14 2020-05-19 Modernatx, Inc. Zika virus MRNA vaccines
WO2019115635A1 (en) 2017-12-13 2019-06-20 Curevac Ag Flavivirus vaccine
JP2019106895A (ja) * 2017-12-15 2019-07-04 インダストリー‐ユニバーシティー コーぺレーション ファンデーション ハンヤン ユニバーシティ 神経幹細胞または神経前駆細胞からドーパミン神経細胞への分化方法
KR102206657B1 (ko) * 2017-12-15 2021-01-22 한양대학교 산학협력단 신경줄기세포 또는 신경전구세포에서 도파민 신경세포로의 분화방법
MA54676A (fr) 2018-01-29 2021-11-17 Modernatx Inc Vaccins à base d'arn contre le vrs
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
MX2022007680A (es) 2019-12-20 2022-09-26 Curevac Ag Nanoparticulas lipidicas para administracion de acidos nucleicos.
JP2023535365A (ja) 2020-07-16 2023-08-17 アクイタス セラピューティクス インコーポレイテッド 脂質ナノ粒子に使用するためのカチオン性脂質
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
WO2022261075A1 (en) 2021-06-07 2022-12-15 The Board Of Trustees Of The University Of Illinois Photoactivatable gasdermin proteins
CA3230031A1 (en) 2021-09-03 2023-03-09 Patrick Baumhof Novel lipid nanoparticles for delivery of nucleic acids
AU2022336664A1 (en) 2021-09-03 2024-01-18 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1412591A (en) * 1971-11-30 1975-11-05 Beecham Group Ltd Antiviral ds rna and compositions thereof
WO1999014346A2 (en) 1997-09-19 1999-03-25 Sequitur, Inc. SENSE mRNA THERAPY
US5945400A (en) * 1995-02-17 1999-08-31 Rhone-Poulenc Rorer Sa Nucleic acid-containing composition, preparation and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2676072B1 (fr) * 1991-05-03 1994-11-18 Transgene Sa Vecteur de delivrance d'arn.
KR100252547B1 (ko) * 1991-09-05 2000-09-01 프레드 마리얀스키 폴리-또는 올리고누클레오티드의 세포로의 표적화된 전달

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1412591A (en) * 1971-11-30 1975-11-05 Beecham Group Ltd Antiviral ds rna and compositions thereof
US5945400A (en) * 1995-02-17 1999-08-31 Rhone-Poulenc Rorer Sa Nucleic acid-containing composition, preparation and use thereof
WO1999014346A2 (en) 1997-09-19 1999-03-25 Sequitur, Inc. SENSE mRNA THERAPY

Non-Patent Citations (30)

* Cited by examiner, † Cited by third party
Title
BOCZKOWSKI, D.; NAIR, S. K.; SNYDER, D.; GILBOA, E.: "Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo", J. EXP. MED., vol. 184, 1996, pages 465 - 472
CARBONE, F. R.; BEVAN, M. J.: "Class I-restricted processing and presentation of exogenous cell-associated antigen in vivo", J.EXP. MED., vol. 171, 1990, pages 377 - 387
CONOLLY, J. H.: "Effect of Histones and Protamine on the Infectivity of Semliki Forest Virus and its Ribonucleic Acid", NATURE, vol. 19, 1966, pages 858
CONRY R M ET AL: "CHARACTERIZATION OF A MESSENGER RNA POLYNUCLEOTIDE VACCINE VECTOR", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 55, no. 7, 1 April 1995 (1995-04-01), pages 1397 - 1400, XP000576177, ISSN: 0008-5472 *
DERES, K.; SCHILD, H.; WIESMÜLLER, K-H.; JUNG, G.; RAMMENSEE, H.-G.: "In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine", NATURE, vol. 342, 1989, pages 561 - 564
DUBES G R ET AL: "RAPID EPHEMERAL CELL SENSITIZATION AS THE MECHANISM OF HISTONE- INDUCED AND PROTAMINE-INDUCED ENHANCEMENT OF TRASNFECTION BY POLIOVIRUS RNA", PROTOPLASMA, SPRINGER VERLAG, VIENNA, AT, vol. 96, 1978, pages 209 - 223, XP000575919, ISSN: 0033-183X *
DUBES, G. R.; WEGRZYN, R. J.: "Rapid Ephemeral Cell Sensitization as the Mechanism of Histone-Induced and Protamine-Induced Enhancement of Transfection by Poliovirus RNA", PROTOPLASMA, vol. 96, 1978, pages 209 - 223
FALK, K.; ROTZSCHKE, 0.; FAATH, S.; GOTH, S.; GRAEF, I.; SHASTRI, N.; RAMMENSEE, H.-G.: "Both human and mouse cells expressing H-2Kb and ovalbumin process the same peptide, SIINFEKL", CELL IMMUNOL., vol. 150, 1993, pages 447 - 52
FILION, M. C.; PHILLIPS, N. C.: "Toxicity and immunomodu- latory activity of liposomal vectors formulated with cationic lipids toward immune effector cells", BIOCHIM. BIOPHYS. ACTA, vol. 1329, 1997, pages 245 - 356
FISHER K J ET AL: "THE TRANSMEMBRANE DOMAIN OF DIPHTHERIA TOXIN IMPROVES MOLECULAR CONJUGATE GENE TRANSFER", BIOCHEMICAL JOURNAL, PORTLAND PRESS, LONDON, GB, vol. 321, no. 1, 1997, pages 49 - 58, XP000867796, ISSN: 0264-6021 *
FLECHSLER I ET AL: "Comparison of antisense vectors and antisense oligonucleotides delivered by means of the new cationic lipids unifectin and maxifectin.", ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY. 1998, vol. 451, 1998, pages 469 - 472, XP009048306, ISSN: 0065-2598 *
FÖRG, P.; VON HOEGEN, P.; DALEMANS, W.; SCHIRRMACHER V.: "Superiority of the ear pinna over muscle tissue as site for DNA vaccination", GENE THER., vol. 5, 1998, pages 789 - 797
GAVIN, M.A.; GILBERT, M. J.; RIDDELL, S. R.; GREENBERG, P. D.; BEVAN M. J.: "Alkali hydrolysis of recombinant proteins allows for the rapid identification of class I MHC-restricted CTL epitopes", J. IMMUNOL., vol. 151, 1993, pages 3971 - 3980
GILKESON G. S.; PIPPEN, A. M.; PISETSKY, D. S.: "Induction of cross-reactive anti-dsDNA antibodies in preautoimmune NZB/NZW mice by immunization with bacterial DNA", J. CLIN. INVEST., vol. 95, 1995, pages 1398 - 1402
LIU, M. A.; FU, T. M.; DONNELLY, J. J.; CAULFIELD, M. J.; ULMER, J. B.: "DNA vaccines. Mechanisms for generation of immune responses", ADV. EXP. MED. BIOL., vol. 452, 1998, pages 187 - 191
MALONE R W ET AL: "CATIONIC LIPOSOME-MEDIATED RNA TRANSFECTION", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 86, no. 16, 1 August 1989 (1989-08-01), pages 6077 - 6081, XP000604642, ISSN: 0027-8424 *
MALONE, R. W.; FELGNER, P. L.; VERMA, I.: "cationic liposome-mediated RNA transfection", PROC. NATL. ACAD. SCI. USA, vol. 86, 1989, pages 6077 - 6081
MARTINON, F.; KRISHNAN, S.; LENZEN, G.; MAGNE, R.; GOMARD, E.; GUILLET, J-G.; LEVY J-P.; MEULIEN, P.: "Induction of virus specific cytotoxic T Iymphocytes in vivo by liposome entrapped mRNA", EUR. J. IMMUNOL., vol. 23, 1993, pages 1719 - 1722
MARTINS, L. P.; LAU, L. L.; ASANO, M. S.; AHMED, R.: "DNA vaccination against persistent viral infection", J. VIROL., vol. 69, 1995, pages 2574 - 2582
MONTGOMERY, D. L. ET AL.: "Heterologous and homologous protection against influenza A by DNA vaccination: Optimiza tion of DNA vectors", DNA AND CELL BIOLOGY, vol. 12, 1993, pages 777 - 783
OUKKA, M.; COHEN-TANNOUDJI, M.; TANAKA, Y.; BABINET, C; KOSMATOPOULOS, K.: "Medullary thymic epithelial cells induce tolerance to intracellular proteins", J. IMMUNOL., vol. 156, 1996, pages 968 - 975
RAMMENSEE, H.-G.; SCHILD, H.; THEOPOLD, U.: "Protein-specific cytotoxic T lymphocytes. Recognition of transfectants expressing intracellular, membrane-associated or secreted forms of B-galactosidase", IMMUNOGENETICS, vol. 30, 1989, pages 296 - 302
SAWAI KEISUKE ET AL: "A novel method of cell-specific mRNA transfection", MOLECULAR GENETICS AND METABOLISM, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 64, no. 1, May 1998 (1998-05-01), pages 44 - 51, XP002245185, ISSN: 1096-7192 *
SCHILD, H.; NORDA, M.; DERES, K.; FALK, K.; ROTZSCHKE, 0.; WIESMULLER, K.-H.; JUNG, G.; RAMMENSEE, H.-G.: "Fine specifity of cytotoxic T lymphocytes primed in vivo either with virus or synthetic lipopeptide vaccine or primed in vitro with peptide", J. EXP. MED., vol. 174, 1991, pages 1665 - 1668
SMULL C E ET AL: "Enhancement of the plaque-forming capacity of poliovirus ribonucleic acid with basic proteins.", JOURNAL OF BACTERIOLOGY. NOV 1962, vol. 84, November 1962 (1962-11-01), pages 1035 - 1040, XP002330080, ISSN: 0021-9193 *
STRONG, T. V.; HAMPTON, T. A.; LOURO, I.; BILBAO, G.; CONRY, R. M.; CURIEL,. D. T.: "Incorporation of B-globin untranslated regions into a sindbis virus vector for augmentation of heterologous mRNA expression", GENE THER., vol. 4, 1997, pages 624 - 627
TAMURA, Y.; PENG, P.; LIU, K.; DAOU, M.; SRIVASTAVA, P. K.: "Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations", SCIENCE, vol. 278, 1997, pages 117 - 120
WARRANT, R. W.; KIM, S. H.: "Alpha-Helix-double helix interaction shown in the structure of a protamine-transfer RNA complex and a nucleoprotamine model", NATURE, vol. 27, 1978, pages 130 - 135
WOLFF, J. A.; MALONE, R. W.; WILLIAMS, P.; CHONG, W.; ACSADI, G.; FELGNER, P. L.: "Direct gene transfer into mouse- muscle in vivo", SCIENCE, vol. 257, 1990, pages 1465 - 1468
YING, H.; ZAKS, T. Z.; WANG, R.; IRVINE, K. R.; KAMMULA, U. S.; MARINCOLA, F. M.; LEITNER, W. W.; RESTIFO, N. P.: "Cancer therapy using a self-replicating RNA vaccine", NATURE MEDICINE, vol. 5, 1999, pages 823 - 827

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2101823B1 (de) 2007-01-09 2016-11-23 CureVac AG Rna-kodierter antikörper
US11421038B2 (en) 2007-01-09 2022-08-23 Curevac Ag RNA-coded antibody
US9937233B2 (en) 2010-08-06 2018-04-10 Modernatx, Inc. Engineered nucleic acids and methods of use thereof
US9657295B2 (en) 2010-10-01 2017-05-23 Modernatx, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US10898574B2 (en) 2011-03-31 2021-01-26 Modernatx, Inc. Delivery and formulation of engineered nucleic acids
US11911474B2 (en) 2011-03-31 2024-02-27 Modernatx, Inc. Delivery and formulation of engineered nucleic acids
US10751386B2 (en) 2011-09-12 2020-08-25 Modernatx, Inc. Engineered nucleic acids and methods of use thereof
US10577403B2 (en) 2012-04-02 2020-03-03 Modernatx, Inc. Modified polynucleotides for the production of secreted proteins
US9828416B2 (en) 2012-04-02 2017-11-28 Modernatx, Inc. Modified polynucleotides for the production of secreted proteins
US10772975B2 (en) 2012-04-02 2020-09-15 Modernatx, Inc. Modified Polynucleotides for the production of biologics and proteins associated with human disease
US9814760B2 (en) 2012-04-02 2017-11-14 Modernatx, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US10385106B2 (en) 2012-04-02 2019-08-20 Modernatx, Inc. Modified polynucleotides for the production of secreted proteins
US9827332B2 (en) 2012-04-02 2017-11-28 Modernatx, Inc. Modified polynucleotides for the production of proteins
US10703789B2 (en) 2012-04-02 2020-07-07 Modernatx, Inc. Modified polynucleotides for the production of secreted proteins
US11845772B2 (en) 2013-03-15 2023-12-19 Modernatx, Inc. Ribonucleic acid purification
US10590161B2 (en) 2013-03-15 2020-03-17 Modernatx, Inc. Ion exchange purification of mRNA
US11377470B2 (en) 2013-03-15 2022-07-05 Modernatx, Inc. Ribonucleic acid purification
US10138507B2 (en) 2013-03-15 2018-11-27 Modernatx, Inc. Manufacturing methods for production of RNA transcripts
US10077439B2 (en) 2013-03-15 2018-09-18 Modernatx, Inc. Removal of DNA fragments in mRNA production process
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10858647B2 (en) 2013-03-15 2020-12-08 Modernatx, Inc. Removal of DNA fragments in mRNA production process
US11027025B2 (en) 2013-07-11 2021-06-08 Modernatx, Inc. Compositions comprising synthetic polynucleotides encoding CRISPR related proteins and synthetic sgRNAs and methods of use
US10815291B2 (en) 2013-09-30 2020-10-27 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
US10385088B2 (en) 2013-10-02 2019-08-20 Modernatx, Inc. Polynucleotide molecules and uses thereof
US10709779B2 (en) 2014-04-23 2020-07-14 Modernatx, Inc. Nucleic acid vaccines
US9872900B2 (en) 2014-04-23 2018-01-23 Modernatx, Inc. Nucleic acid vaccines
US10286086B2 (en) 2014-06-19 2019-05-14 Modernatx, Inc. Alternative nucleic acid molecules and uses thereof
US10407683B2 (en) 2014-07-16 2019-09-10 Modernatx, Inc. Circular polynucleotides
US11434486B2 (en) 2015-09-17 2022-09-06 Modernatx, Inc. Polynucleotides containing a morpholino linker
EP4035659A1 (de) 2016-11-29 2022-08-03 PureTech LYT, Inc. Exosome zur ausgabe von therapeutischen wirkstoffen

Also Published As

Publication number Publication date
DE69943068D1 (de) 2011-02-03
EP1083232A1 (de) 2001-03-14
ATE289630T1 (de) 2005-03-15
EP1541690A2 (de) 2005-06-15
ES2238799T3 (es) 2005-09-01
EP1541690A3 (de) 2005-07-27
EP1083232B1 (de) 2005-02-23
EP1619254B1 (de) 2010-12-22
DE69923840D1 (de) 2005-03-31
ATE492644T1 (de) 2011-01-15
DE69923840T2 (de) 2006-04-06
EP1818409A1 (de) 2007-08-15

Similar Documents

Publication Publication Date Title
EP1619254B1 (de) Transfer von mRNA unter Verwendung von polykationischen Verbindungen
JP7465310B2 (ja) 多用途性且つ効率的な遺伝子発現のためのｒｎａレプリコン
Hoerr et al. In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies
JP7421256B2 (ja) トランス複製型ｒｎａ
Minigo et al. Poly-L-lysine-coated nanoparticles: a potent delivery system to enhance DNA vaccine efficacy
EP0918848B1 (de) Methode zur behandlung von krebs und pathogenen infektionen unter verwendung von antigen-präsentierenden zellen beladen mit rna
Diken et al. mRNA: a versatile molecule for cancer vaccines
Jechlinger Optimization and delivery of plasmid DNA for vaccination
Běláková et al. DNA vaccines: are they still just a powerful tool for the future?
Giese DNA-antiviral vaccines: new developments and approaches—a review
ZA200308390B (en) Novel expression vectors and uses thereof
WO2023066874A1 (en) Methods for determining mutations for increasing modified replicable rna function and related compositions and their use
AU7251596A (en) Stimulation of cell-mediated immune responses by targeted particulate genetic immunization
US7176186B1 (en) Stimulation of cell-mediated immune responses by targeted particulate genetic immunization
US20070258993A1 (en) Dna-Carrier Conjugate
Little et al. Nonviral delivery of cancer genetic vaccines
Hasan Messenger RNA Based Vaccines and Their immunological effect on diseases
JP2023527910A (ja) 多用途かつ効率的な遺伝子発現のためのｒｎａレプリコン
Schmidt et al. MIDGE vectors and dSLIM immunomodulators: DNA-based molecules for gene therapeutic strategies
Probst et al. 11 Messenger RNA Vaccines
Bereta et al. 16 DNA Vaccines
NZ785741A (en) Trans-replicating RNA

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051017

AC Divisional application: reference to earlier application

Ref document number: 1083232

Country of ref document: EP

Kind code of ref document: P

Ref document number: 1541690

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: JUNG, GUENTHER, PROF. DR.

Inventor name: HOERR, INGMAR

Inventor name: OBST, REINHARD, DR.

Inventor name: RAMMENSEE, HANS-GEORG, PROF. DR.

AKX Designation fees paid

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20080108

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

RIN1 Information on inventor provided before grant (corrected)

Inventor name: RAMMENSEE, HANS-GEORG, PROF. DR.

Inventor name: HOERR, INGMAR, DR.

Inventor name: OBST, REINHARD, DR.

Inventor name: JUNG, GUENTHER, PROF. DR.

AC Divisional application: reference to earlier application

Ref document number: 1083232

Country of ref document: EP

Kind code of ref document: P

Ref document number: 1541690

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69943068

Country of ref document: DE

Date of ref document: 20110203

Kind code of ref document: P

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 69943068

Country of ref document: DE

Effective date: 20110203

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: PATENTANWALTSKANZLEI NUECKEL

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20101222

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101222

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101222

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101222

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101222

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110323

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110402

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110422

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101222

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101222

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101222

26N No opposition filed

Effective date: 20110923

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101222

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 69943068

Country of ref document: DE

Effective date: 20110923

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110930

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110909

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110909

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 17

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20160926

Year of fee payment: 18

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20170925

Year of fee payment: 19

Ref country code: GB

Payment date: 20170925

Year of fee payment: 19

Ref country code: DE

Payment date: 20170717

Year of fee payment: 19

REG Reference to a national code

Ref country code: CH

Ref legal event code: PCAR

Free format text: NEW ADDRESS: OBERDORFSTRASSE 16, 8820 WAEDENSWIL (CH)

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170930

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170930

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 69943068

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20180909

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190402

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180909